Translational perspective
Our present study reveals that CXCL1-CXCR2 axis is essential for monocyte infiltration into the heart and cardiac remodelling induced by angiotensin II. Blocking of CXCL1 and CXCR2 activation or ablation of CXCR2 effectively prevents adverse cardiac remodelling. Thus, pharmacological targeting of CXCL1-CXCR2 signalling may
Introduction
Adverse cardiac remodelling is now recognized as a determinant of the clinical course of heart failure (HF), which is still one of the leading causes of death worldwide. 1 This process is mainly influenced by haemodynamic load and neuro-hormonal activation. 2 Among the neuro-humoral factors, angiotensin (Ang) II, a key component of the renin-angiotensin system (RAS), plays an important role in the pathogenesis of cardiac remodelling in a variety of diseases. 3 Interestingly, pharmacological or genetic interventions that inhibit RAS activity have been shown to reduce cardiac inflammation and improve HF. 3 There is growing evidence to support the critical role of inflammatory cells especially monocytes/macrophages in the pathophysiology of HF in both animal and human research. 4 Therefore, it is important to identify the mechanisms that attract these cells into the heart after hypertensive stress to prevent cardiac dysfunction.
Chemokines are a family of inflammatory cytokines that have ability to induce the directional migration and activation of leucocytes. They are classified into four distinct classes, based on a shared cysteine motif: CC (CCL1-28), CXC (CXCL1-17), CX3C (CX3C1), and C (XCL1-2). Chemokines exert their biological functions via cell-surface receptors, which are designated as CCRs, CXCRs, CX3CRs, and XCRs. Increasing evidence suggests that these chemokines play a fundamental role in recruiting neutrophils, monocytes, and lymphocytes to the injured heart. 5 Interestingly, several chemokines [MIP-1a, MIP-1b, RANTES, CXCL1 and interleukin (IL)-8, and CXCL5] and their receptors (CCR1, CCR2, CCR5, CCR7, CXCR1, CXCR2, and CX3CR) have been found in animal models and patients with hypertrophy and HF, and some of them are closely related to the disease severity. 6, 7 Among them, CXC chemokine CXCL1 and its receptor CXCR2 play a critical role in promoting the recruitment of neutrophils and monocytes/macrophages into the injured heart and arterial wall, thereby inducing myocardial infarction, ischaemia/ reperfusion injury, atherosclerosis, and hypertension. [8] [9] [10] Recent studies have demonstrated that monocytes have been implicated in the pathogenesis of Ang II-induced hypertension and cardiac remodelling. 4, [11] [12] [13] Therefore, it is important to explore whether the CXCL1-CXCR2 axis induces recruitment of monocytes into the heart and has a critical role in Ang II-induced cardiac remodelling.
In this study, we showed that bone marrow (BM)-derived CXCR2 þ monocytes are involved in Ang II-induced adverse cardiac remodelling and dysfunction. The levels of CXCL1 and CXCR2 were markedly upregulated in Ang II-induced hypertrophic heart and blood of HF patients. The inhibition of CXCL1 and CXCR2 or deletion of CXCR2 significantly reduced Ang II-induced infiltration of monocytes into the heart thereby improving cardiac remodelling and dysfunction. Therefore, these results provide novel evidence supporting that inhibition of CXCL1-CXCR2 signalling exerts a cardio-protective role and representing a new therapeutic target for hypertensive cardiac remodelling.
Methods Animals
Wild-type (WT) mice (C57BL/6J, male) and CXCR2 knockout mice [CXCR2 KO, B6.129S2(C)-Cxcr2 tm1Mwm
/J] at 8-12 weeks of age were used to establish the cardiac remodelling model by subcutaneous infusion of Ang II at a dose of 1000 ng/kg/min as described previously. 13 The anti-CXCL1 antibody (100 lg/mice/day) and CXCR2 inhibitor SB265610 (2 mg/kg/day) were administrated intraperitoneally to WT mice beginning 1 day before Ang II infusion and continued during Ang II treatment (Supplementary material online).
Flow cytometry
The inflammatory cells in the heart tissues were analysed by flow cytometry (Supplementary material online).
Histological study
Heart samples, fixed in 4% paraformaldehyde and embedded in paraffin, were used for the quantification of cardiac hypertrophy, fibrosis, and inflammatory cells (Supplementary material online).
Bone marrow chimeric mice
Chimeric mice were used to examine the contribution of BM-derived CXCR2-positive cells to cardiac hypertrophic remodelling (Supplementary material online).
Human study populations
We explored the patients with HF with reduced ejection fraction (EF%) (n = 32) and age-and sex-matched control subjects (n = 30) in a monocentric clinical cohort between August 2017 and October 2017. Heart failure patients were diagnosed according to the 2016 ESC Guidelines.
1
The baseline characteristics of control subjects and patients are indicated in Table 1 (Supplementary material online).
Statistics
All data are expressed as mean ± standard deviation (SD). The statistical analysis was performed by SPSS 16.0 (Supplementary material online).
Results
Angiotensin II increases CXCL1 and CXCR2 expression and CXCR2-positive myelomonocyte infiltration in the heart
To investigate the role of CXCL1 and CXCR2 in cardiac remodelling, we first performed microarray analysis to examine the chemokine gene expression in Ang II-infused hearts on Day 1. Among the 12 chemokine genes, CXCL1 was the most markedly upregulated (12.5-fold) in Ang II-infused hearts compared with control hearts ( Figure 1A) . The increased expression of CXCL1 was validated by quantitative PCR analysis and immunohistochemical staining ( Figure 1B and C) in the same hearts. Moreover, its receptor CXCR2 expression at the mRNA and protein levels was also significantly increased in Ang II-infused hearts at different time points ( Figure 1D and E). Flow cytometry showed that CXCR2 was predominantly expressed in monocytes/macrophages (77.7%) and neutrophils (70.6%) but not in T cells in the hearts ( Figure 1F Figure S1A ). Echocardiography revealed that CXCL1 antibody markedly reversed Ang II-induced cardiac contractile dysfunction as reflected by left ventricular (LV) EF% and fractional shortening (FS%) compared with IgG-treated mice ( Figure 2A , Supplementary material online, Table S2 ). Moreover, Ang II infusion-induced cardiac hypertrophy as indicated by an increase in the heart size, heart weight to tibial length (HW/TL) ratio, the cross-sectional area of myocytes as well as the expression of hypertrophic markers atrial natriuretic factor (ANF) and brain natriuretic peptide (BNP) were markedly attenuated in CXCL1 antibody-treated animals ( Figure 2B-D) . Similarly, there was a significant increase in peripheral and interstitial fibrosis, asmooth muscle actin (a-SMA)-positive myofibroblasts, and the expression of a-SMA, collagen I and collagen III in CXCL1 antibodytreated animals compared with IgG-treated mice ( Figure 2E-G) . Interestingly, Ang II-stimulated infiltration of inflammatory cells, especially Mac-2-positive macrophages and CXCR2 þ cells and the expression of IL-1b, IL-6, or IL-13 were markedly lower in CXCL1 antibody-treated mice ( Figure 2H and I). There was no significant difference in these parameters between two groups after saline infusion (Figure 2A-I) . These results suggest that CXCL1 contributes to Ang II-induced cardiac dysfunction and hypertrophic remodelling.
Ablation of CXCR2 attenuates angiotensin II-induced cardiac hypertrophy and fibrosis
We next tested the role of CXCR2 in regulating cardiac remodelling in WT and CXCR2 KO mice. After 2 weeks of Ang II infusion, systolic blood pressure elevation (Supplementary material online, Figure S1B ) and cardiac contractile dysfunction (EF% and FS%) in WT mice were markedly improved in CXCR2 KO mice ( Figure 3A , Supplementary material online, Table S3 ). Moreover, CXCR2 KO significantly reduced Ang II-induced cardiac hypertrophy (increased heart size, HW/TL ratio, myocyte area, and the expression of ANF and BNP) compared with WT mice ( Figure 3B-D) . Accordingly, LV fibrosis, a-SMA-positive myofibroblasts and the expression of a-SMA, collagen I, and collagen III were less visible in CXCR2 KO hearts ( Figure 3E -G).
We next determined which signalling pathways are involved in myocyte hypertrophy and fibrosis and found that Ang II-induced increase in the protein levels of p-AKT, p-ERK1/2, p-STAT3, calcineurin A (CaNA), transform growth factor b1 (TGF-b1), or p-Smad2/3 were all remarkably downregulated in CXCR2 KO hearts compared with WT controls ( Figure 3H and I). There was no statistically significant difference in these pathological features between two groups at baseline ( Figure 3A-I 
þ neutrophils in the hearts after angiotensin II infusion (left). The percentage of each type cells (right, n = 6). Data are presented as mean ± standard deviation, and n represents number of samples or animals.
CXCL1-CXCR2 axis regulates hypertensive cardiac remodelling Figure 4A) . Interestingly, CD3 þ T cells were similar between WT and CXCR2 KO mice after saline or Ang II infusion ( Figure 4A ). Haematoxylin and eosin (H&E) staining and quantitative real-time polymerase chain reaction (qPCR) analysis further confirmed that deletion of CXCR2 in mice remarkably abrogated Ang IIinduced recruitment of pro-inflammatory cells and the expression of IL-1b, IL-6, tumour necrosis factor-a (TNF-a), and monocyte chemoattractantprotein-1 (MCP-1) compared with WT controls ( Figure 4B and C). In addition, we detected NF-jB activation, a key regulator for pro-inflammatory cytokine expression and myocardial injury. Angiotensin II-induced P65 activation was markedly lower in CXCR2 KO mice than in WT hearts ( Figure 4D ). Thus, these data indicate that CXCR2 mediates accumulation of pro-inflammatory cells that likely contribute to adverse cardiac remodelling and dysfunction.
Therapeutic administration of CXCR2 inhibitor SB265610 blunts angiotensin II-induced cardiac hypertrophy, fibrosis, and inflammation
To further test whether inhibition of CXCR2 improves Ang II-induced adverse cardiac remodelling, WT mice were treated with a CXCR2-specific antagonist SB265610 (2 mg/kg, once a day) and Ang II for 2 weeks. Wild-type mice displayed characteristics of hypertension (Supplementary material online, Figure S1C ), cardiac dysfunction (increased EF% and FS%), and hypertrophy (increase in heart size, HW/TL ratio, myocyte area, and the expression of ANF and BNP), which were significantly attenuated in SB265610-treated mice ( Figure  5A -D, Supplementary material online, Table S4 ). Furthermore, less myocardial fibrosis, a-SMA-positive myofibroblasts, and the expression of a-SMA, collagen I and collagen III were obtained in SB265610-treated hearts compared with vehicle-treated controls ( Figure 5E-G) .
There was no significant difference in these parameters between two groups after saline infusion (Supplementary material online, Figure  S1C , Figure 5A -G). Consistent with the findings from CXCR2 KO mice, flow cytometry confirmed that SB265610 treatment also significantly reduced myocardial infiltration of CD45 þ myelomonocytes, CD11b þ F4/80 þ macrophages and CD11b þ Gr-1 þ neutrophils compared with vehicle-treated controls after Ang II infusion (Supplementary material online, Figure S2A ). Moreover, Ang II-induced myocardial recruitment of pro-inflammatory cells and the expression of IL-1b, IL-6, TNF-a, and MCP-1 were markedly lower in SB265610-treated mice than in vehicle-treated animals (Supplementary material online, Figure S2B and C).
Bone marrow-derived CXCR2-deficient cells attenuates angiotensin II-induced cardiac hypertrophy, fibrosis, and inflammation
To directly test whether CXCR2 þ myeloid cells affect cardiac remodelling, we created various chimeric mice by BM transplant and infused them with Ang II for the ensuing 2 weeks. WT mice reconstituted with CXCR2 KO BM exhibited a significant decrease in systolic blood pressure (Supplementary material online, Figure S3 ), improvement of contractile function (EF% and FS%) ( Figure 6A , Supplementary material online, Table S5 ), hypertrophy (HW/TL ratio and myocyte area) ( Figure  6B and C) and fibrosis (collagen area and a-SMA-positive myofibroblasts) ( Figure 6E and F) , infiltration of pro-inflammatory cells ( Figure  6H ) and the mRNA expression of ANF, BNP, a-SMA, collagen I and collagen III, IL-6, IL-1b, TNF-a and MCP-1 ( Figure 6D, G, I ) as compared to WT mice reconstituted with WT BM. Similar effects were confirmed in CXCR2 KO mice reconstituted with CXCR2 KO BM ( Figure  6A-I) . Conversely, reconstitution of CXCR2 KO mice with WT BM fully restored Ang II-induced pathological changes ( Figure 6A-I ). These findings suggest that BM-derived CXCR2 cells predominantly contribute to the development of hypertrophic remodelling in this model.
CXCR2-deficient macrophages inhibit cardiomyocyte hypertrophy and myofibroblast differentiation in vitro
We next determined whether CXCR2 influences macrophage migration and activation in vitro. A transwell migration assay showed that CXCL1 treatment significantly enhanced migration of WT macrophages (U), but it had no significant effect on CXCR2 KO macrophages (Supplementary material online, Figure S4A ). Quantitative realtime polymerase chain reaction and enzyme linked immunosorbent assay (ELISA) analysis confirmed that Ang II-induced up-regulation of IL-1b, IL-6, TGF-b1, ICAM-1, VCAM-1, or MCP-1 at both the mRNA and protein levels in WT macrophages was markedly attenuated in CXCR2 KO macrophages compared with WT cells (Supplementary material online, Figure S4B and C). Moreover, activation of P65 was also significantly inhibited in CXCR2 KO macrophages compared with WT cells after Ang II infusion (Supplementary material online, Figure S4D ). To test whether CXCR2 þ macrophages directly influenced cardiomyocyte (CM) hypertrophy and myofibroblast differentiation in vitro, WT or CXCR2 KO macrophages were co-cultured with WT neonatal rat cardiac myocytes (CMs) or fibroblasts (CFs), respectively. After 24 h of Ang II treatment, co-culture of CMs with CXCR2 KO macrophages had a significant reduction in CM size, the expression of ANF, BNP and b-MHC, and the protein levels of p-AKT, p-ERK1/2, p-STAT3 and CaNA compared with co-culture of CMs with WT macrophages (Supplementary material online, Figure S4E -G).
Meanwhile, co-culture of CFs with CXCR2 KO macrophages markedly attenuated Ang II-induced increase in the mRNA levels of a-SMA, collagen I, collagen III or TGF-b1 compared with co-culture of CFs with WT macrophages (Supplementary material online, Figure S4H) . Similarly, the protein levels of a-SMA, collagen I, collagen III, TGF-b1, or p-Smad2/3 were remarkably lower in co-culture of CFs with CXCR2 KO macrophages after Ang II treatment (Supplementary material online, Figure S4I ). 
Serum CXCL1 level and CXCR2
þ inflammatory cells are increased in heart failure patients with hypertension
To test whether CXCR2 þ monocytes and CXCL1 are important in human hypertensive HF, we analysed serum CXCR2 þ immune cells, CXCL1 level, and other cardiovascular risk factors in HF patients (n = 30) and normal individuals (n = 32). Heart failure patients were older and had higher total cholesterol, LDL, triglyceride, and lower HDL concentrations compared with normal controls ( Table 1) . Flow cytometry analysis revealed that the numbers of circulating 
monocytes, and CXCL1 level were significantly higher in HF patients than in normal individuals ( Figure 7A-I) . After adjusting for gender, age, total cholesterol, LDL, HDL, and triglycerides, multivariable logistic regression models indicated that there was a statistically significant association between the number of CXCR2 þ cells, including CD45 þ cells [odds ratio (OR)
þ monocytes (OR 1.106), CXCL1 level (OR 1.386), and HF ( Table 2) .
Discussion
Here, we demonstrated for the first time that CXCL1-CXCR2 signalling induces myocardial recruitment of monocytes, which is 
þ monocytes, and
þ monocytes in normotensive people (n = 32) and heart failure patients (n = 30). (I) ELISA assay of serum CXCL1 levels in normotensive people (n = 32) and heart failure patients (n = 30). Data are presented as mean ± standard deviation and n represents number of persons.
. Angiotensin II infusion significantly upregulated CXCL1 expression, which promoted the infiltration of BM-derived CXCR2 þ monocytes into the heart tissues and produced multiple proinflammatory cytokines, thereby causing cardiac remodelling and dysfunction. Conversely, therapeutic blocking of CXCL1 and CXCR2 or ablation of CXCR2 markedly attenuated these effects.
Thus, our novel evidence supports a strong causative role of CXCL1-CXCR2 axis in the pathogenesis of cardiac remodelling. A working model is illustrated in Figure 8 . It is well known that pro-inflammatory cells play pivotal roles in the development of cardiovascular diseases. 14 12, 13, [18] [19] [20] Chemokines are reported to be critically involved in leucocyte trafficking to the inflammatory sites, and their principal targets are haematopoietic cells. 5 Interestingly, these chemokines are markedly upregulated upon heart injury to induce a chemotactic response in vivo. 5 CXCL1 has been reported to exert a critical role in different cardiovascular diseases by regulating the recruitment of neutrophils, T lymphocytes and monocytes. 11, 21 In this study, we extended previous findings and found that CXCL1 was also significantly upregulated in Ang II-infused hearts ( Figure 1 ) and HF patients (Figure 8 ), which recruited CXCR2 þ monocytes into the heart tissues leading to cardiac remodelling, but this effect was prevented by CXCL1 neutralizing antibody (Figure 2 ). Further studies are required to determine how CXCL1 is upregulated by Ang II in the heart. CXCL1 exerts multiple biological functions via binding to its CXCR2 receptor, which also serves as a receptor for other CXCL subfamily members.
5 CXCR2 is reported to be express on the surface of both immune and non-immune cells, including leucocytes, T lymphocytes, CMs, and CFs, and it regulates the functions of these cells. Interestingly, CXCR2 activation plays critical roles in the recruitment of leucocytes and neutrophils, which are involved in the pathogenesis of myocardial infarction and atherosclerosis. 8, 9 Our recent data indicated that CXCR2 mainly mediates infiltration of monocytes into the injured arteries leading to hypertension. 11 Here, we further demonstrated that genetic and pharmacological inhibition of CXCR2 effectively reduced Ang II-induced infiltration of monocytes/macrophages and cardiac remodelling through inhibition of multiple signalling pathways in vivo and in vitro (Figures 3-6 , Supplementary material online, Figure S4 ). Overall, our results suggest that CXCR2 þ monocytes/macrophages directly contribute to Ang IIinduced cardiac remodelling and dysfunction. This study identified for the first time that CXCL1-CXCR2 axis induced recruitment of monocytes/macrophages into the heart thereby leading to cardiac remodelling and dysfunction in response to Ang II. Circulating CXCR2 þ monocytes and CXCL1 level were significantly higher in HF patients. Therapeutic targeting of CXCL1 or CXCR2 signalling prevented adverse cardiac remodelling and dysfunction, thus representing an attractive new strategy for treating hypertensive HF.
